Skip to main content
SpringerLink
Log in

IL-2- Therapie beim SLE – Selektive Rekonstitution immunologischer Toleranz

IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance

  • Neues aus der Forschung
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Malek TR (2008) The biology of interleukin-2. Annu Rev Immunol 26:453–479

    Article  CAS  PubMed  Google Scholar 

  2. Sadlack B, Lohler J, Schorle H et al (1995) Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25(11):3053–3059

    Article  CAS  PubMed  Google Scholar 

  3. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6(11):1142–1151

    Article  CAS  PubMed  Google Scholar 

  4. Ohl K, Tenbrock K (2016) Regulatory T‑cells in systemic lupus erythematosus: IL-2 is decisive for loss of tolerance. Z Rheumatol. (Epub ahead of print; German)

  5. Humrich JY, Morbach H, Undeutsch R et al (2010) Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci USA 107(1):204–209

    Article  CAS  PubMed  Google Scholar 

  6. Crispin JC, Alcocer-Varela J (1998) Interleukin-2 and systemic lupus erythematosus – fifteen years later. Lupus 7(4):214–222

    Article  CAS  PubMed  Google Scholar 

  7. Spee-Mayer C von, Siegert E, Abdirama D et al (2015) Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-207776

    Google Scholar 

  8. Saadoun D, Rosenzwajg M, Joly F et al (2011) Regulatory T‑cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365(22):2067–2077

    Article  CAS  PubMed  Google Scholar 

  9. Koreth J, Matsuoka K, Kim HT et al (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365(22):2055–2066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Humrich JY, Spee-Mayer C von, Siegert E et al (2015) Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis 74(4):791–792

    Article  PubMed  Google Scholar 

  11. Klatzmann D, Abbas AK (2015) The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 15(5):283–294

    Article  CAS  PubMed  Google Scholar 

  12. Long SA, Rieck M, Sanda S et al (2012) Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 61(9):2340–2348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    J. Y. Humrich & G. Riemekasten

Authors
  1. J. Y. Humrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Riemekasten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Y. Humrich.

Ethics declarations

Interessenkonflikt

J. Y. Humrich und G. Riemekasten geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

A. Radbruch, Berlin

H. Schulze-Koops, München

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Humrich, J.Y., Riemekasten, G. IL-2- Therapie beim SLE – Selektive Rekonstitution immunologischer Toleranz. Z Rheumatol 75, 490–492 (2016). https://doi.org/10.1007/s00393-016-0129-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-016-0129-8

Search

Navigation